UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2016.
Commission File Number: 001-37384
GALAPAGOS NV
(Translation of registrant's name into English)
Generaal De Wittelaan L11 A3
2800 Mechelen, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F [ x ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
On May 17, 2016 the Registrant issued a press release, a copy of which is
attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c) Exhibit 99.1. Press
release dated May 17, 2016
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GALAPAGOS NV (Registrant) | ||
| Date: May 17, 2016 | /s/ XAVIER MAES Xavier Maes Company Secretary |
Exhibit 99.1
Regulated information
Listing of existing shares on Euronext Brussels & Amsterdam
Mechelen, Belgium; 17 May 2016, 7.00 CET: Galapagos (Euronext & NASDAQ: GLPG) announces that, following the approval of a listing prospectus by the Belgian Financial Services and Markets Authority, the 6,760,701 shares subscribed to by Gilead on 19 January 2016 have been admitted to trading on Euronext Brussels and Amsterdam today. A copy of the listing prospectus is available on our website at www.glpg.com.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development
of small molecule medicines with novel modes of action. Our maturing pipeline comprises Phase 2, Phase 1, pre-clinical and discovery
studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib:
in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the
world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos
group, including fee-for-service subsidiary Fidelta, has approximately 440 employees, operating from its Mechelen, Belgium headquarters
and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com.
Contacts
| Investors: | Media: |
| Elizabeth Goodwin | Evelyn Fox |
| VP IR & Corporate | Director Communications |
| Communications | +31 6 53 591 999 |
| +1 781 460 1784 | communications@glpg.com |
| Paul van der Horst | |
| Director IR & Business | |
| Development | |
| +31 6 53 725 199 | |
| ir@glpg.com |
Forward-looking statements
This release may contain forward-looking statements, all of which involve certain risks and uncertainties. These statements are
often, but not always, made through the use of words or phrases such as "anticipates," "believes," "continues,"
"could," "estimates," "expects," "intends," "may," "plans," "seeks,"
"stands to," "we believe," "will," "we intend," as well as similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition
and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or
future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements.
In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in
which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in
future periods. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments,
clinical trial and product development activities and regulatory approval requirements (including that data from Galapagos' ongoing
clinical research programs may not support registration or further development of its product candidates due to safety, efficacy
or other reasons), Galapagos' reliance on collaborations with third parties, and estimating the commercial potential of Galapagos'
product candidates. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities
and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on form 20-F filed with the
SEC and subsequent filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to
place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document
to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any
such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking
statements, unless specifically required by law or regulation.